EDC1

**EDC1** is a preclinical **antibody-drug conjugate** developed by **Centrose Pharmaceuticals** for metastatic cancers, with pancreatic cancer highlighted in the company pipeline. It is a non-internalizing **extracellular drug conjugate** built from the anti-dysadherin antibody **NCC-M53** linked through a proprietary long non-cleavable linker to **CEN-106**, a Na,K-ATPase inhibitor. EDC1 targets **dysadherin** on metastatic cancer cells and associated stromal elements, enabling payload action at the cell surface rather than after intracellular internalization. The reported mechanism is inhibition of **Na,K-ATPase** signaling/function on dysadherin-expressing cells, leading to loss of cellular electrical homeostasis and necrotic cancer cell death. Public company and publication materials describe activity in pancreatic cancer mouse models and additional preclinical work in thyroid cancer, melanoma, non-small-cell lung cancer, and hematologic malignancy models.

Other names

extracellular drug conjugate 1anti-dysadherin extracellular drug conjugatedysadherin extracellular drug conjugate